HRP20210747T1 - Fizički i kemijski stabilne oralne suspenzije givinostata - Google Patents

Fizički i kemijski stabilne oralne suspenzije givinostata Download PDF

Info

Publication number
HRP20210747T1
HRP20210747T1 HRP20210747TT HRP20210747T HRP20210747T1 HR P20210747 T1 HRP20210747 T1 HR P20210747T1 HR P20210747T T HRP20210747T T HR P20210747TT HR P20210747 T HRP20210747 T HR P20210747T HR P20210747 T1 HRP20210747 T1 HR P20210747T1
Authority
HR
Croatia
Prior art keywords
vol
suspension
suspension according
agent
givinostat
Prior art date
Application number
HRP20210747TT
Other languages
English (en)
Croatian (hr)
Inventor
Giuseppe Colombo
Roberta Artico
Paolo Mascagni
Maria Valmen MONZANI
Silvia PUCCIANTI
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of HRP20210747T1 publication Critical patent/HRP20210747T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
HRP20210747TT 2015-11-03 2016-10-28 Fizički i kemijski stabilne oralne suspenzije givinostata HRP20210747T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITUB2015A005193A ITUB20155193A1 (it) 2015-11-03 2015-11-03 Sospensioni orali di Givinostat fisicamente e chimicamente stabili
EP16805507.7A EP3370697B1 (en) 2015-11-03 2016-10-28 Physically and chemically stable oral suspensions of givinostat
PCT/IB2016/056496 WO2017077436A1 (en) 2015-11-03 2016-10-28 Physically and chemically stable oral suspensions of givinostat

Publications (1)

Publication Number Publication Date
HRP20210747T1 true HRP20210747T1 (hr) 2021-06-25

Family

ID=55410062

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210747TT HRP20210747T1 (hr) 2015-11-03 2016-10-28 Fizički i kemijski stabilne oralne suspenzije givinostata

Country Status (31)

Country Link
US (1) US10688047B2 (enExample)
EP (1) EP3370697B1 (enExample)
JP (1) JP6800970B2 (enExample)
KR (1) KR102603894B1 (enExample)
CN (2) CN113368044B (enExample)
AR (1) AR106559A1 (enExample)
AU (1) AU2016349169B2 (enExample)
BR (1) BR122024001653A2 (enExample)
CA (1) CA3002755C (enExample)
CL (1) CL2018001151A1 (enExample)
CO (1) CO2018003971A2 (enExample)
CY (1) CY1124092T1 (enExample)
DK (1) DK3370697T3 (enExample)
ES (1) ES2870201T3 (enExample)
FI (1) FIC20250035I1 (enExample)
HR (1) HRP20210747T1 (enExample)
HU (1) HUE054123T2 (enExample)
IL (1) IL258608B (enExample)
IT (1) ITUB20155193A1 (enExample)
LT (1) LT3370697T (enExample)
MX (1) MX380361B (enExample)
NZ (1) NZ741467A (enExample)
PE (1) PE20181369A1 (enExample)
PL (1) PL3370697T3 (enExample)
PT (1) PT3370697T (enExample)
RS (1) RS61694B1 (enExample)
RU (1) RU2721396C2 (enExample)
SI (1) SI3370697T1 (enExample)
SM (1) SMT202100161T1 (enExample)
TW (1) TWI727983B (enExample)
WO (1) WO2017077436A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7373991B2 (ja) 2016-07-15 2023-11-06 ビラクタ セラピューティクス,インク. 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
IT201900003281A1 (it) * 2019-03-06 2020-09-06 Chemi Spa Processo per preparare {6-[(dietilammino)metil]naftalen-2-il}metil [4-(idrossicarbamoil)fenil]carbammato ad elevata purezza
KR20220034736A (ko) 2019-05-31 2022-03-18 비락타 서브시디어리 인크. 히스톤 데아세틸라제 억제제를 사용하여 바이러스 관련 암을 치료하는 방법
WO2022088037A1 (zh) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Sirtinol在制备预防和治疗冠状病毒的药物中的应用
CN114306311A (zh) * 2022-01-14 2022-04-12 同济大学 组蛋白去乙酰化酶抑制剂在制备治疗心脏病的药物中的应用
CN116173003A (zh) * 2023-02-24 2023-05-30 山西医科大学 药物吉维司他在治疗阿尔茨海默病中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169150A (en) * 1975-11-12 1979-09-25 Teijin Limited Benzodiazepine derivatives and pharmaceutical compositions containing said derivatives
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
PL371133A1 (en) * 2001-12-20 2005-06-13 Pharmacia Corporation Pharmaceutical suspension for oral administration
EA006707B1 (ru) 2002-03-13 2006-02-24 Янссен Фармацевтика Н. В. Сульфонилпроизводные в качестве новых ингибиторов гистон-деацетилазы
ITMI20030063A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
PT1611088E (pt) 2003-04-07 2009-09-24 Pharmacyclics Inc Hidroxamatos como agentes terapêuticos
NZ542711A (en) 2003-08-20 2008-03-28 Pharmacyclics Inc Acetylene derivatives as inhibitors of histone deacetylase
ITMI20041347A1 (it) 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
WO2006010750A1 (en) 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
WO2006018814A2 (en) * 2004-08-16 2006-02-23 Ranbaxy Laboratories Limited Oral liquid suspensions of metaxalone
CA2645205C (en) * 2006-05-19 2012-12-04 Norbrook Laboratories Limited Stable aqueous suspension having palatable taste
SG174772A1 (en) 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
AU2010313290A1 (en) * 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
IT1397912B1 (it) * 2010-01-28 2013-02-04 Chemi Spa Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
WO2011113013A2 (en) * 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
TW201245115A (en) * 2011-01-24 2012-11-16 Chdi Foundation Inc Histone deacetylase inhibitors and compositions and methods of use thereof
EP2809313A1 (en) * 2012-02-03 2014-12-10 Italfarmaco SpA Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy
WO2014165226A2 (en) * 2013-03-12 2014-10-09 Synedgen, Inc. Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar
WO2014159224A1 (en) 2013-03-14 2014-10-02 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
WO2015086738A2 (en) 2013-12-11 2015-06-18 Bionor Immuno As Hiv vaccine

Also Published As

Publication number Publication date
RU2721396C2 (ru) 2020-05-19
AU2016349169B2 (en) 2021-11-11
DK3370697T3 (da) 2021-04-26
PL3370697T3 (pl) 2021-07-12
BR122024001653A2 (pt) 2024-03-05
MX380361B (es) 2025-03-12
PE20181369A1 (es) 2018-08-27
CN113368044B (zh) 2023-06-02
JP2019501116A (ja) 2019-01-17
US10688047B2 (en) 2020-06-23
RU2018120170A (ru) 2019-12-05
CN108366956B (zh) 2021-09-10
ITUB20155193A1 (it) 2017-05-03
HK1254811A1 (en) 2019-07-26
EP3370697B1 (en) 2021-02-17
BR112018008870A2 (pt) 2018-11-06
LT3370697T (lt) 2021-06-10
SI3370697T1 (sl) 2021-04-30
SMT202100161T1 (it) 2021-05-07
JP6800970B2 (ja) 2020-12-16
CL2018001151A1 (es) 2018-12-07
CN113368044A (zh) 2021-09-10
CO2018003971A2 (es) 2018-07-19
CN108366956A (zh) 2018-08-03
MX2018004505A (es) 2018-09-12
CY1124092T1 (el) 2022-05-27
PT3370697T (pt) 2021-04-06
ES2870201T3 (es) 2021-10-26
CA3002755C (en) 2022-10-18
AR106559A1 (es) 2018-01-24
AU2016349169A1 (en) 2018-05-17
WO2017077436A1 (en) 2017-05-11
TW201722401A (zh) 2017-07-01
RS61694B1 (sr) 2021-05-31
US20180311160A1 (en) 2018-11-01
EP3370697A1 (en) 2018-09-12
HUE054123T2 (hu) 2021-08-30
CA3002755A1 (en) 2017-05-11
IL258608A (en) 2018-06-28
KR20180082468A (ko) 2018-07-18
IL258608B (en) 2022-06-01
KR102603894B1 (ko) 2023-11-20
RU2018120170A3 (enExample) 2019-12-05
FIC20250035I1 (fi) 2025-12-05
NZ741467A (en) 2021-07-30
TWI727983B (zh) 2021-05-21
BR112018008870A8 (pt) 2019-02-26

Similar Documents

Publication Publication Date Title
HRP20210747T1 (hr) Fizički i kemijski stabilne oralne suspenzije givinostata
WO2012051426A3 (en) Aggregate nanoparticulate medicament formulations, manufacture and use thereof
Gadhave Determination of hydrophilic-lipophilic balance value
RU2011141422A (ru) Водные суспензии рилузола
Rub et al. Aggregational behaviour of promethazine hydrochloride and TX-45 surfactant mixtures: A multi-techniques approach
JP2014098212A5 (enExample)
MX2014011122A (es) Composicion estabilizante para materiales biologicos.
MX382837B (es) Composición y método para el crecimiento del pelo.
AU2008261509A1 (en) Suspension concentrate of Zn thiodiazole and preparation thereof
EP2985020B1 (en) Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer
RU2017146716A (ru) Способ образования наночастиц циклоспорина а/ циклодекстрина
HK1214951A1 (zh) 眼用製劑
HK1198942A1 (en) Concentrated felbamate formulations for parenteral administration
FI3258920T3 (fi) Juomavesilääkkeenä käytettäväksi soveltuva kiinteä farmaseuttinen annosmuoto
CN203414098U (zh) 一种简易悬挂手动调平平台
WO2015017182A3 (en) Method of making granular detergent compositions comprising surfactants
AR091694A1 (es) Proceso para la produccion de un granulo detergente, granulo detergente y composicion detergente que comprende dicho granulo
WO2021069345A1 (en) Process for producing nanoparticulate rivaroxaban
KR101021619B1 (ko) 안정성이 증진된 알파-리포익산의 나노입자 제제 및 그제조방법
US20240003034A1 (en) Composite dispersant, preparation method therefor, mixed electroplating solution, and preparation method therefor
CN205770125U (zh) 一种可互换分散受力起落架
CN100356905C (zh) 使用控制沉淀(重结晶)法制备的结晶药物微粒
US20240050370A1 (en) Triple stabilizer system
Li et al. Fabrication of nanoporous copper ribbons by dealloying of Mn70Cu30 alloy and fractal characterization of their porosity
RU2011135958A (ru) Тонко измельченная фармацевтическая композиция